Extended Data Fig. 3: Workflow of RaDaR panel generation and ctDNA assessment in plasma and urine. | Nature Medicine

Extended Data Fig. 3: Workflow of RaDaR panel generation and ctDNA assessment in plasma and urine.

From: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Extended Data Fig. 3

DNA was isolated from baseline tumor sample and from PBMCs and used for whole-exome sequencing to identify tumor-specific somatic mutations. A personalized ctDNA assay was developed for each patient. Cell-free DNA and buffy coat DNA from EDTA-plasma and urine samples were analyzed together with tumor DNA using the personalized assays to confirm somatic mutations and perform CHIP filtering. PBMCs: peripheral blood mononuclear cells, ctDNA: circulating tumor DNA, CHIP: clonal hematopoiesis of indeterminate potential.

Back to article page